News
-
-
PRESS RELEASE
Marinomed Biotech AG seeks reorganisation through restructuring proceedings without self-administration
Marinomed Biotech seeks reorganisation through restructuring proceedings without self-administration due to outstanding earn-out payments and terminated negotiations with Unither Pharmaceuticals -
-
PRESS RELEASE
EQS-Adhoc: Ad-hoc: Marinomed Biotech AG files for court restructuring proceedings without self-administration
Marinomed Biotech AG files for court restructuring proceedings without self-administration. Market making contract terminated, affecting share liquidity. Half-year financial report postponed -
-
-
-
PRESS RELEASE
Original-Research: Marinomed Biotech AG (von First Berlin Equity Research GmbH): Under Review
First Berlin Equity Research GmbH has updated its recommendation and price target on Marinomed Biotech AG (ATMARINOMED6) to UNDER REVIEW following the company's announcement of filing for court-supervised restructuring proceedings to address insolvency risk -
-
PRESS RELEASE
EQS-Adhoc: Ad-hoc: Marinomed Biotech AG plans to apply for court restructuring proceedings without self-administration
Marinomed Biotech AG to apply for court restructuring proceedings without self-administration due to failed negotiations and insolvency risk. Aim to secure financial stability
